Nonhormonal systemic therapy for advanced breast cancer: Do the math!

Journal of the National Cancer Institute

Volumn 100, Issue 24, 2008, Pages 1745-1747

  Bedard, Philippe L ^a   Piccart Gebhart, Martine J ^a,b  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; HUMAN; META ANALYSIS; MONOTHERAPY; PATIENT SELECTION; PRIORITY JOURNAL; SURVIVAL TIME; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 58049194211     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn433     Document Type: Editorial

References (25)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988;319 (26):1681-1692.
2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365 (9472):1687-1717.
3. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001;93 (13):979-989.
4. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18 (7):1133-1144.
5. Peto R. Early Breast Cancer Trialists' Collaborative Group. The worldwide overview: new results for systemic adjuvant therapies. Breast Cancer Res Treatment. 2007;106 (suppl 1):5. San Antonio, USA : Presented at the 30th Annual San Antonio Breast Cancer Symposium. December, 13-16.
6. Bedard PL, Krzyzanowska MK, Pintilie M, Tannock IF. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. J Clin Oncol. 2007;25 (23):3482-3487.
7. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998;16 (10):3439-3460.
8. Jones D, Ghersi D, Wilcken N. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev. 2006;3:CD003368.
9. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26 (12):1980-1986.
10. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JPA. Multiple treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008;100 (24):1780-1791.
11. Thomas L. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21 (16):2313-2324.
12. Song F, Altman DG, Glenny A-M, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J. 2003;326 (7387):472-476.
13. Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet. 2006;368 (9546):1503-1515.
14. Thijs V, Lemmens R, Fieuws S. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. Eur Heart J. 2008;29 (9):1086-1092.
15. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26 (24):3950-3957.
16. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20 (12):2812-2823.
17. Beslija S, Obralic N, Basic H. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). J Clin Oncol. 2006;24 (18S):571.
18. Carrick S, Parker S, Wilcken N, Ghersi D, Marzo M, Simes J. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2005 ;(2):CD003372.
19. NCI. FDA approval for ixabepilone. http://www.cancer.gov/cancertopics/ druginfo/fda-ixabepilone. Last accessed: November 19, 2008.
20. NCI. FDA approval for bevacizumab. http://www.cancer.gov/cancertopics/ druginfo/fda-bevacizumab. Last accessed: November 19, 2008.
21. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26 (12):1987-1992.
22. Chia SK, Speers CH, D'Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110 (5):973-979.
23. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005;104 (8):1742-1750.
24. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100 (1):44-52.
25. Dawood SS, Kristine B, Hortobagyi GN, Giordano SH. Prognosis of women with stage IV breast cancer by HER2 status and trastuzumab treatment: an institutional based review [abstract 1018]. J Clin Oncol. 2008(suppl ):26 (15s); abstract (1018).